{"id":827397,"date":"2025-03-19T07:46:50","date_gmt":"2025-03-19T11:46:50","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-announce-fourth-quarter-and-full-year-2024-financial-results-and-host-conference-call-on-march-27-2025\/"},"modified":"2025-03-19T07:46:50","modified_gmt":"2025-03-19T11:46:50","slug":"plus-therapeutics-to-announce-fourth-quarter-and-full-year-2024-financial-results-and-host-conference-call-on-march-27-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-announce-fourth-quarter-and-full-year-2024-financial-results-and-host-conference-call-on-march-27-2025\/","title":{"rendered":"Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">HOUSTON, March  19, 2025  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3Ae_3phkt9a0vRK8YYeq5Ev12ANeaVL2pLGrlshAF0LSw2q5kqN-GoKQZb23g8PYQTH22PV8R4Lzj_jk-uVJIEXlYKO4GSKIWKeiLxdlH7ihxDfMR75uLdfOFDWFsp7Rl4z8_Ae8hpNIgRYjy5rDH3YPOujyW42fI0jRboIahyAs5T4eEL3eaQ8mLMbOw54v3oDfzYIRgjzEXWfwf9j4tsszYCITFOOZG_GMFSUKoU6Fz7raqNhJ2AGohlXdA9L-FfabkugL7P-JDib8XEQ4LQkqGJ198GzjUH9YU1Mf2KMapSTXT1hRjWp22VbgkqcolTGviFazLoKvbbtmbdXRlopfXLbUBV16cYaoqy09D-qHg-83STZ5Egf2iV_Sn1CTbgEMbundkbP4OOwBYVgDE7mKXhXgQI3qfvYCKRtJumiDs2TDyjFnPv_oThZQ7b1etGzhW9Kfz5rTgwpNwi9lQW58OcajVo67OLXM8w0CqOYw7OMpgIcB1jtfyDjx2arE\" rel=\"nofollow\" target=\"_blank\">Plus Therapeutics, Inc.<\/a> (Nasdaq:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6fWn5UMN4145ROJgxsqVZ-UCdIy6YXIHGvgfFvzkVNQhBfKiO4IaKcCCoNcl0a2EHaJfMcVFspDLkbPhYGtZSsYLnLYOVWHV0QbopIHlnmQ3NGgwgSx2wkHxMPqDSWaoaO69ZPqQEZYzPb78Xq8qfZd9Rx1dF3Qx9g09Q-xbl3EL6-RJvMxrVGwZ0YIora3OsI3ZLWetBkWCNbeMsJFGNvh232Jkl_IpLq8uL-0hRjr5NXKGEfLiaYrXt_O8wkh1PFpU2VKYip9S4vPkSBp6GI-A57BbvIrgpRRjM-DJ4ISmPOsucy3N1xeqR6B4JO9htOEMbQA5HN9EUpsnWa_YYdUU72WOan5FcGeyQlpHaC1o6Jur-jAm6ULgZdTriSY5Q8ZPDJ6Xj1P5T0W3BmzJYugtQo8QHsOXLchGzcQ4HK3X9ZsZ4CHrIplz_2GEmp14\" rel=\"nofollow\" target=\"_blank\">PSTV<\/a>) (the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces that the Company will report fourth quarter and full year 2024 financial results on Thursday, March 27, 2025 after market close. Plus Therapeutics\u2019 management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update.<\/p>\n<p align=\"justify\">\n        <strong>Webcast and Conference Call<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:15%;width:15%;min-width:15%;vertical-align: top\">Date\/Time:<\/td>\n<td style=\"max-width:85%;width:85%;min-width:85%;vertical-align: top\">Thursday, March 27, 2025 @ 5:00 PM ET<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">Webcast:<\/td>\n<td style=\"vertical-align: top\">\n            <a href=\"https:\/\/edge.media-server.com\/mmc\/p\/5r5hkcqq\" rel=\"nofollow\" target=\"_blank\">https:\/\/edge.media-server.com\/mmc\/p\/5r5hkcqq<\/a>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">Dial-in Link:<\/td>\n<td style=\"vertical-align: top\">\n            <a href=\"https:\/\/register-conf.media-server.com\/register\/BI74b28f5ee02c4c1c89a835bfb6bdc1c8\" rel=\"nofollow\" target=\"_blank\">https:\/\/register-conf.media-server.com\/register\/BI74b28f5ee02c4c1c89a835bfb6bdc1c8<\/a>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">\u00a0<\/td>\n<td style=\"vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">Participants are encouraged to pre-register any time before the call through the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ihcBEE0gACERfsqOVBqUhAWPyUfFnS8U3r17gJ8Mafk9Z0HU8YNESgvQm-arKP3-JxDhwsNcMZ4wYJ5hVp6vkcs8XHueitexrYFoU0RzCZbI23x11RbSGdQLzmo4SfHRT4v3FXfVKqQQX0aJnBYvaFqFhGwbaetNs2No-sZPCjY=\" rel=\"nofollow\" target=\"_blank\">dial-in link<\/a>. Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the start time.<\/p>\n<p align=\"justify\">Following the live call, a replay will be available on the Company\u2019s website under the \u2018For Investors\u2019 section. The webcast will be available on the Company\u2019s website for 90 days following the live call.<\/p>\n<p align=\"justify\">\n        <strong>About Plus Therapeutics<\/strong><br \/>\n        <br \/>Headquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. For more information, visit https:\/\/plustherapeutics.com\/.<\/p>\n<p align=\"justify\">\n        <strong>Cautionary Statement Regarding Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains statements that may be deemed \u201cforward-looking statements\u201d within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as \u201cexpect\u201d \u201cpotential,\u201d \u201canticipating,\u201d \u201cplanning\u201d and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate.<\/p>\n<p align=\"justify\">These statements include, without limitation, statements under the heading Upcoming Events and Expected Milestones, and statements regarding the following: CLIA compliance certification of the Company\u2019s Houston-based clinical laboratory; the potential promise of rhenium (186Re) obisbemeda; expectations as to the Company\u2019s future performance, including the next steps in developing the Company\u2019s product candidates; the Company\u2019s clinical trials, including statements regarding the timing and characteristics of the ReSPECT-GBM, ReSPECT-LM and ReSPECT-PBC clinical trials; the continued evaluation of rhenium (186Re) obisbemeda including through evaluations in additional patient cohorts;; development and utility of CNSide leptomeningeal metastases diagnostic test.<\/p>\n<p align=\"justify\">The forward-looking statements included in this press release could differ materially from those expressed or implied by these forward-looking statements because of risks, uncertainties, and other factors that include, but are not limited to, the following: the early stage of the Company\u2019s product candidates and therapies; the results of the Company\u2019s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company\u2019s liquidity and capital resources and its ability to raise additional cash; the outcome of the Company\u2019s partnering\/licensing efforts, risks associated with laws or regulatory requirements applicable to it, including the ability of the Company to come into compliance with The Nasdaq Capital Market listing requirements; market conditions, product performance, litigation or potential litigation, and competition within the cancer diagnostics and therapeutics field; ability to develop and protect proprietary intellectual property or obtain licenses to intellectual property developed by others on commercially reasonable and competitive terms; challenges associated with radiotherapeutic manufacturing, production and distribution capabilities necessary to support the Company\u2019s clinical trials and any commercial level product demand; and material security breach or cybersecurity attack affecting the Company\u2019s operations or property. This list of risks, uncertainties, and other factors is not complete. Plus Therapeutics discusses some of these matters more fully, as well as certain risk factors that could affect Plus Therapeutics\u2019 business, financial condition, results of operations, and prospects, in its reports filed with the SEC, including Plus Therapeutics\u2019 annual report on Form 10-K for the fiscal year ended December 31, 2023, quarterly reports on Form 10-Q, and current reports on Form 8-K. These filings are available for review through the SEC\u2019s website at www.sec.gov. Any or all forward-looking statements Plus Therapeutics makes may turn out to be wrong and can be affected by inaccurate assumptions Plus Therapeutics might make or by known or unknown risks, uncertainties, and other factors, including those identified in this press release. Accordingly, you should not place undue reliance on the forward-looking statements made in this press release, which speak only as of its date. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.<\/p>\n<p align=\"justify\">\n        <strong>Investor Contact<\/strong><br \/>\n        <br \/>Jules Abraham<br \/>Managing Director, Communications<br \/>CORE IR<br \/>Julesa@coreir.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTYxOCM2ODA5NDQzIzIwMDQ4MDU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NzQwMzJkNjUtZWFhNi00YzRhLWI2OTgtMTdmOWY4ZDEzN2M4LTEwMTYzNzgtMjAyNS0wMy0xOS1lbg==\/tiny\/Plus-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>HOUSTON, March 19, 2025 (GLOBE NEWSWIRE) &#8212; Plus Therapeutics, Inc. (Nasdaq:\u00a0PSTV) (the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces that the Company will report fourth quarter and full year 2024 financial results on Thursday, March 27, 2025 after market close. Plus Therapeutics\u2019 management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update. Webcast and Conference Call Date\/Time: Thursday, March 27, 2025 @ 5:00 PM ET Webcast: https:\/\/edge.media-server.com\/mmc\/p\/5r5hkcqq Dial-in Link: https:\/\/register-conf.media-server.com\/register\/BI74b28f5ee02c4c1c89a835bfb6bdc1c8 \u00a0 \u00a0 Participants are encouraged to pre-register any time before the call through the dial-in link. Once registration is completed, participants will be &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-announce-fourth-quarter-and-full-year-2024-financial-results-and-host-conference-call-on-march-27-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-827397","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-announce-fourth-quarter-and-full-year-2024-financial-results-and-host-conference-call-on-march-27-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"HOUSTON, March 19, 2025 (GLOBE NEWSWIRE) &#8212; Plus Therapeutics, Inc. (Nasdaq:\u00a0PSTV) (the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces that the Company will report fourth quarter and full year 2024 financial results on Thursday, March 27, 2025 after market close. Plus Therapeutics\u2019 management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update. Webcast and Conference Call Date\/Time: Thursday, March 27, 2025 @ 5:00 PM ET Webcast: https:\/\/edge.media-server.com\/mmc\/p\/5r5hkcqq Dial-in Link: https:\/\/register-conf.media-server.com\/register\/BI74b28f5ee02c4c1c89a835bfb6bdc1c8 \u00a0 \u00a0 Participants are encouraged to pre-register any time before the call through the dial-in link. Once registration is completed, participants will be &hellip; Continue reading &quot;Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-announce-fourth-quarter-and-full-year-2024-financial-results-and-host-conference-call-on-march-27-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-19T11:46:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTYxOCM2ODA5NDQzIzIwMDQ4MDU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-to-announce-fourth-quarter-and-full-year-2024-financial-results-and-host-conference-call-on-march-27-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-to-announce-fourth-quarter-and-full-year-2024-financial-results-and-host-conference-call-on-march-27-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025\",\"datePublished\":\"2025-03-19T11:46:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-to-announce-fourth-quarter-and-full-year-2024-financial-results-and-host-conference-call-on-march-27-2025\\\/\"},\"wordCount\":904,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-to-announce-fourth-quarter-and-full-year-2024-financial-results-and-host-conference-call-on-march-27-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NTYxOCM2ODA5NDQzIzIwMDQ4MDU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-to-announce-fourth-quarter-and-full-year-2024-financial-results-and-host-conference-call-on-march-27-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-to-announce-fourth-quarter-and-full-year-2024-financial-results-and-host-conference-call-on-march-27-2025\\\/\",\"name\":\"Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-to-announce-fourth-quarter-and-full-year-2024-financial-results-and-host-conference-call-on-march-27-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-to-announce-fourth-quarter-and-full-year-2024-financial-results-and-host-conference-call-on-march-27-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NTYxOCM2ODA5NDQzIzIwMDQ4MDU=\",\"datePublished\":\"2025-03-19T11:46:50+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-to-announce-fourth-quarter-and-full-year-2024-financial-results-and-host-conference-call-on-march-27-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-to-announce-fourth-quarter-and-full-year-2024-financial-results-and-host-conference-call-on-march-27-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-to-announce-fourth-quarter-and-full-year-2024-financial-results-and-host-conference-call-on-march-27-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NTYxOCM2ODA5NDQzIzIwMDQ4MDU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NTYxOCM2ODA5NDQzIzIwMDQ4MDU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-to-announce-fourth-quarter-and-full-year-2024-financial-results-and-host-conference-call-on-march-27-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-announce-fourth-quarter-and-full-year-2024-financial-results-and-host-conference-call-on-march-27-2025\/","og_locale":"en_US","og_type":"article","og_title":"Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025 - Market Newsdesk","og_description":"HOUSTON, March 19, 2025 (GLOBE NEWSWIRE) &#8212; Plus Therapeutics, Inc. (Nasdaq:\u00a0PSTV) (the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces that the Company will report fourth quarter and full year 2024 financial results on Thursday, March 27, 2025 after market close. Plus Therapeutics\u2019 management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update. Webcast and Conference Call Date\/Time: Thursday, March 27, 2025 @ 5:00 PM ET Webcast: https:\/\/edge.media-server.com\/mmc\/p\/5r5hkcqq Dial-in Link: https:\/\/register-conf.media-server.com\/register\/BI74b28f5ee02c4c1c89a835bfb6bdc1c8 \u00a0 \u00a0 Participants are encouraged to pre-register any time before the call through the dial-in link. Once registration is completed, participants will be &hellip; Continue reading \"Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-announce-fourth-quarter-and-full-year-2024-financial-results-and-host-conference-call-on-march-27-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-19T11:46:50+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTYxOCM2ODA5NDQzIzIwMDQ4MDU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-announce-fourth-quarter-and-full-year-2024-financial-results-and-host-conference-call-on-march-27-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-announce-fourth-quarter-and-full-year-2024-financial-results-and-host-conference-call-on-march-27-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025","datePublished":"2025-03-19T11:46:50+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-announce-fourth-quarter-and-full-year-2024-financial-results-and-host-conference-call-on-march-27-2025\/"},"wordCount":904,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-announce-fourth-quarter-and-full-year-2024-financial-results-and-host-conference-call-on-march-27-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTYxOCM2ODA5NDQzIzIwMDQ4MDU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-announce-fourth-quarter-and-full-year-2024-financial-results-and-host-conference-call-on-march-27-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-announce-fourth-quarter-and-full-year-2024-financial-results-and-host-conference-call-on-march-27-2025\/","name":"Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-announce-fourth-quarter-and-full-year-2024-financial-results-and-host-conference-call-on-march-27-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-announce-fourth-quarter-and-full-year-2024-financial-results-and-host-conference-call-on-march-27-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTYxOCM2ODA5NDQzIzIwMDQ4MDU=","datePublished":"2025-03-19T11:46:50+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-announce-fourth-quarter-and-full-year-2024-financial-results-and-host-conference-call-on-march-27-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-announce-fourth-quarter-and-full-year-2024-financial-results-and-host-conference-call-on-march-27-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-announce-fourth-quarter-and-full-year-2024-financial-results-and-host-conference-call-on-march-27-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTYxOCM2ODA5NDQzIzIwMDQ4MDU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTYxOCM2ODA5NDQzIzIwMDQ4MDU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-announce-fourth-quarter-and-full-year-2024-financial-results-and-host-conference-call-on-march-27-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/827397","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=827397"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/827397\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=827397"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=827397"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=827397"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}